Dr. Yu- Chieh Tsai

Claim this profile

National Taiwan University Hospital

Studies Skin Cancer
Studies Transitional Cell Carcinoma
1 reported clinical trial
4 drugs studied

Area of expertise

1Skin Cancer
Yu- Chieh Tsai has run 1 trial for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
2Transitional Cell Carcinoma
Yu- Chieh Tsai has run 1 trial for Transitional Cell Carcinoma. Some of their research focus areas include:
Stage IV
Stage III

More about Yu- Chieh Tsai

Clinical Trial Related2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Yu- Chieh Tsai has experience with
  • Avelumab
  • M6223
  • NKTR-255
  • Sacituzumab Govitecan
Breakdown of trials Yu- Chieh Tsai has run
Transitional Cell Carcinoma

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yu- Chieh Tsai specialize in?
Yu- Chieh Tsai focuses on Skin Cancer and Transitional Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Yu- Chieh Tsai currently recruiting for clinical trials?
No, Yu- Chieh Tsai is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Yu- Chieh Tsai has studied deeply?
Yes, Yu- Chieh Tsai has studied treatments such as Avelumab, M6223, NKTR-255.
What is the best way to schedule an appointment with Yu- Chieh Tsai?
Apply for one of the trials that Yu- Chieh Tsai is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.